GGrantIndex
← Leaderboards

Jing Wang

University Of Nebraska Medical Center

$7,390,496
Attributed
$7,390,496
Total exposure
6
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.3M · FY201022
$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22

Funding mix

By agency

NIH$7,390,496 · 6

By mechanism

R01$6,760,741 · 4
P20$419,923 · 1
P30$209,832 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Nebraska Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Neoplasm Metastasis

Research focus

Neoplasm MetastasisTransforming Growth Factor BetaMediatingPathway InteractionsCancer CellColorectal CancerSignal TransductionColon CarcinomaMalignant NeoplasmsMolecularCellsMouse ModelTumorBiologicalEffective TherapyEventClinically SignificantClinically RelevantSamplingCancer EtiologyBaseKnock-DownMortalityCancer Therapy

Grant awards (27)

The Functional Role of LGR5 in Colon Cancer$349,713
R01 · FY2022 · CA · contact PI
The Functional Role of GRM3 in Colon Cancer$349,713
R01 · FY2022 · CA · contact PI
The Functional Role of GRM3 in Colon Cancer$356,850
R01 · FY2021 · CA · contact PI
Targeting TGFbeta/PDK4 to Overcome Drug Resistance in Colorectal Cancer$356,850
R01 · FY2021 · CA · contact PI
The Functional Role of LGR5 in Colon Cancer$356,850
R01 · FY2021 · CA · contact PI
The Functional Role of LGR5 in Colon Cancer$356,850
R01 · FY2020 · CA · contact PI
Targeting TGFbeta/PDK4 to Overcome Drug Resistance in Colorectal Cancer$356,850
R01 · FY2020 · CA · contact PI
The Functional Role of GRM3 in Colon Cancer$356,850
R01 · FY2020 · CA · contact PI
Target Validation Core$140,074
P20 · FY2020 · GM · contact PI
Laboratory Services (LS)$53,756
P30 · FY2020 · CA · contact PI
Targeting TGFbeta/PDK4 to Overcome Drug Resistance in Colorectal Cancer$346,144
R01 · FY2019 · CA · contact PI
Target Validation Core$143,124
P20 · FY2019 · GM · contact PI
Laboratory Services (LS)$53,756
P30 · FY2019 · CA · contact PI
The Functional Role of GRM3 in Colon Cancer$356,850
R01 · FY2018 · CA · contact PI
The Functional Role of LGR5 in Colon Cancer$356,850
R01 · FY2018 · CA · contact PI
Targeting TGFbeta/PDK4 to Overcome Drug Resistance in Colorectal Cancer$348,653
R01 · FY2018 · CA · contact PI
Target Validation Core$136,725
P20 · FY2018 · GM · contact PI
Laboratory Services (LS)$55,000
P30 · FY2018 · CA · contact PI
Targeting TGFbeta/PDK4 to Overcome Drug Resistance in Colorectal Cancer$346,366
R01 · FY2017 · CA · contact PI
The Functional Role of LGR5 in Colon Cancer$344,269
R01 · FY2017 · CA · contact PI
The Functional Role of GRM3 in Colon Cancer$344,269
R01 · FY2017 · CA · contact PI
Laboratory Services (LS)$47,320
P30 · FY2017 · CA · contact PI
Mechanisms of TGF beta mediated suppression of metastasis in colon cancer$289,927
R01 · FY2014 · CA · contact PI
Mechanisms of TGF beta mediated suppression of metastasis in colon cancer$280,961
R01 · FY2013 · CA · contact PI
Mechanisms of TGF beta mediated suppression of metastasis in colon cancer$298,894
R01 · FY2012 · CA · contact PI
Mechanisms of TGF beta mediated suppression of metastasis in colon cancer$298,894
R01 · FY2011 · CA · contact PI
Mechanisms of TGF beta mediated suppression of metastasis in colon cancer$308,138
R01 · FY2010 · CA · contact PI